
Humana (HUM) Stock Forecast & Price Target
Humana (HUM) Analyst Ratings
Bulls say
Humana is uniquely positioned in the private health insurance sector due to its strong focus on government-sponsored programs, which make up over 95% of its revenue. The company's recent earnings report showed upside on cost trend development and a pragmatic approach to balancing reserve dynamics. This, combined with their commitment to margin preservation and enrollment growth, presents a strong case for a higher EPS baseline and potential earnings recapture in 2026-2027. Additionally, Humana's solid execution and potential for higher peer multiples justify a Buy rating.
Bears say
Humana is facing several challenges that may impede its growth potential in the long term. These include a limited market for its services (focused mainly on government-sponsored programs), potential increases in operating costs (as seen in Q1 where the company experienced higher-than-expected operating costs in their CenterWell segment), and concerns over their ability to achieve guided core MA margin improvement for FY26. These challenges could ultimately harm Humana's profitability and hinder its ability to maintain a strong market position.
This aggregate rating is based on analysts' research of Humana and is not a guaranteed prediction by Public.com or investment advice.
Humana (HUM) Analyst Forecast & Price Prediction
Start investing in Humana (HUM)
Order type
Buy in
Order amount
Est. shares
0 shares